M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...

Centri Business Consulting, LLC, one of the industry's fastest-growing and most respected advisory firms, is excited to announce that its Centri Capital Conference is less than three months away.

Tuesday, financial research firm Cantor Fitzgerald maintained a Neutral stock rating for Desktop Metal Inc. (NYSE:DM) with a consistent price target of $5.00. The firm's analysts highlighted that ...

Cantor Fitzgerald reiterated an Overweight rating on 3D Systems (NYSE:DDD) with a price target of $5.75. Trading at $4.40, InvestingPro analysis suggests the stock is currently undervalued. The firm's ...

In a report released today, Andres Coello from Scotiabank maintained a Buy rating on AST SpaceMobile (ASTS – Research Report), with a price ...

In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Proto Labs (PRLB – Research Report), with a price ...

The authors write "Post-employment restrictive covenants, once viewed as near fortresses to protect proprietary information, ...

Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...

Howard Lutnick, the president’s nominee, is the head of Cantor Fitzgerald LP, which serves as a key banking ... are limited ...

A slew of space stocks have skyrocketed following the inauguration of President Trump, boosted by his vow to champion American space exploration during his administration. Set against this ...

January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the biopharmaceutical company will earn ($1.67) per share for the year. The consensus estimate for Fate Therapeutics’ current ...